Citations

Clear

4847 citation(s) found for "Tu, Eric".

Practice Patterns Regarding Quality Assurance Measures in Gynecologic Cytology: Survey Results of Laboratories Participating in the 2022 College of American Pathologists PAP Education Program
Davey, Diane D. , Souers, Rhona J., Roberson, Janie, Henry, Michael , Russell, Donna K., Teot, Lisa A., Huang, Eric C. , Tabbara, Sana, Goyal, Abha , Russell, Donna K.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | October 3, 2025 | Volume: 150 | Issue: 3 | Pages: 194-201

10.5858/arpa.2025-0187-cp | PMID 41042178 Get It

Context.— Though numerous quality assurance (QA) measures are in place for the practice of gynecologic cytopathology, many of them are not clearly defined and may be variably used by laboratories worldwide. Objective.— To assess current practice patterns regarding the implementation of selected gynecologic cytology QA metrics to help develop guidance for laboratories. Design.— A supplemental questionnaire was mailed to laboratories participating in the 2022 College of American Pathologists (CAP) Gynecologic Cytopathology (PAP Education) Program requesting data regarding their QA measures in gynecologic cytology. Results.— A total of 562 laboratories responded to the supplemental questionnaire; responses from 511 laboratories were analyzed further. Of 492 laboratories, most considered Papanicolaou (Pap) tests from patients with untreated abnormal cytology in the previous year (386; 78.5%) or with an abnormal gynecologic biopsy finding (concurrent or within the past year) (331; 67.3%) as high-risk for negative rescreening. Many laboratories (436 of 511; 85.3%) required pathologist review of Pap tests for indications other than reactive/abnormal cells (eg, endometrial cells in women 45 years of age and older). For assessing cytologists’ performance, 88.5% (399 of 451) of respondents recorded the discrepancy rate between cytologist’s and pathologist’s interpretations. For monitoring pathologists’ performance, most laboratories (243 of 389; 62.5%) evaluated cases with significant cytologic-histologic discrepancy. Conclusions.— The CAP survey provided a detailed assessment of current QA practices regarding gynecologic cytology, which can aid laboratories in making decisions related to enhancement of QA in their setting. As the guidelines and tools for cervical cancer screening evolve, QA metrics will need to be accordingly refined.
Improved prediction of hip fracture using multi-faceted biomechanical computed tomography
Keaveny, Tony M. , Adams, Annette L. , Orwoll, Eric , Khosla, Sundeep , McClung, Michael R. , Bouxsein, Mary , Fatemi, Shireen, Besler, Bryce A. , Lee, David C. , Kopperdahl, David L. , Orwoll, Eric S , Bouxsein, Mary L , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | October 3, 2025 | Volume: 41 | Issue: 5 | Pages: 507-520

10.1093/jbmr/zjaf139 | PMID 41045141 Get It

Abstract With the goal of preventing more hip fractures, a next generation of the VirtuOst Biomechanical Computed Tomography (BCT) test was developed that integrates measurements from a clinical CT scan related to fall risk, impact force, and femoral strength, the three main determinants of hip fracture. Here, we introduce the test and validate it against BMD and FRAX. Our source population from a large healthcare system comprised of 341364 patients (≥65 yr) with an abdominal-pelvic CT during care. Using data from 3035 patients (1790 with hip fracture), we developed a “BCT Risk Score” (range: 0-100) having input risk factors of age, femoral strength, ratio of trabecular/cortical BMD, muscle area, intramuscular fat, FN volume, hip width, and posterior fat thickness. In a geographically distinct set of 2124 patients (1293 with hip fracture), we then compared the BCT Risk Score against a DXA-equivalent hip BMD T-score (lowest hip value, measured from the CT scan by VirtuOst) and FRAX hip fracture risk (with BMD but without parental fracture history) for predicting a first incident hip fracture within 5 yr. For the women, the c-statistic for predicting fracture was higher for BCT (0.89, 95% CI: 0.87-0.90) than for BMD (0.81, 0.79-0.84) or FRAX (0.85, 0.83-0.87). Using binary thresholds to identify high-risk patients, sensitivity for BCT (Risk Score ≥ 75) was higher than for BMD (T-score ≤ −2.5) and FRAX (hip risk ≥ 3.0%): 81.4% vs 47.8% vs 75.9%, respectively; positive predictive values confirmed comparable high-risk status (BCT 13.6% vs BMD 15.3% vs FRAX 12.7%). Similar trends were observed for the men, 2-yr outcomes, and identifying very-high-risk patients. We conclude that, compared to both BMD and FRAX, the integrative BCT test better predicted hip fracture and its high sensitivity should improve fracture prevention.
B-223 DMD Duplications Identified by Carrier Screening Should NOT Automatically Be Classified as [Likely] Pathogenic: Data from Long-Read Sequencing of 15 Cases
Hasadsri, Linda , Ding, Qiliang , Balan, Jagadheshwar, Vidal‐Folch, Noemi, Pickart, Angela, Walsh, Jesse, Majumdar, Ramanath, Klee, Eric W. , Rowsey, Ross, Sun, Guangchao , Murphy, Stephen, Oglesbee, Devin

Mayo Clinic

Clinical Chemistry | October 2, 2025 | Volume: 71 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvaf086.611 Get It

Abstract Background Pathogenic variants in the DMD gene are associated with Duchenne and Becker muscular dystrophy (DMD/BMD). Professional medical societies currently recommend DMD carrier screening for all patients who are pregnant or considering pregnancy. Such testing may identify intragenic duplications of DMD (i.e., involving one or more exons but fully contained with the gene) in patients without a personal or family history of DMD/BMD. These incidentally detected DMD intragenic duplications, however, pose significant challenges for variant interpretation. Pathogenicity of an intragenic duplication depends on its structural configuration. Tandem duplications may cause reading frame disruption and gene loss-of-function; conversely, non-tandem duplications may not disrupt gene function. Current carrier screening assays cannot determine the structural configuration of an intragenic duplication. The current guidelines (e.g., the ClinGen PVS1 decision tree) presume intragenic duplications are in tandem unless proven otherwise. If this presumption of tandem configuration is inaccurate, it may lead to overestimation of variant pathogenicity, potentially resulting in unnecessary invasive procedures (e.g., amniocentesis for prenatal diagnosis) and/or having other negative impacts with regards to prenatal decision-making. This study aims to evaluate the validity of this presumption for incidentally detected DMD intragenic duplications. Methods We performed high-coverage whole-genome long-read sequencing on the PromethION instrument (Oxford Nanopore Technologies) for 15 cases with previously identified DMD intragenic duplications. Among these cases, four had personal or family history of DMD/BMD, while 11 had no known history (i.e., incidentally detected). The structural configurations of the duplications were determined by an in-house bioinformatics tool and manual inspection of the alignment files. Results In all 4 cases with a known personal or family history of DMD/BMD, the DMD intragenic duplications were confirmed to be in tandem, aligning with expectations of their pathogenicity. Interestingly, among the 11 cases with incidentally detected DMD intragenic duplications, seven (64%) were found to involve interspersed duplications. In five of these seven interspersed duplication cases, the involved DMD exons were co-duplicated with distinct segments of the Xp arm located 0.5–30 Mb away, forming complex structural variants. In another case, the duplicated DMD exons have inserted into the Xq arm, about 90 Mb downstream of DMD. The final case involved the duplicated DMD exons inserted into a repetitive region most consistent with 9q12 (i.e., the 9qh region). Conclusions Our study reveals that while DMD intragenic duplications in patients with a personal or family history of DMD/BMD were consistently in tandem, a substantial 64% of incidentally detected DMD intragenic duplications were not in tandem. These findings have important implications for both clinicians and laboratorians. They challenge the presumption of tandem configuration for DMD intragenic duplications in individuals where the variants were identified incidentally, e.g., through carrier screening in those without a family history of DMD/BMD. In these cases, we recommend classifying the DMD intragenic duplications as variants of uncertain significance (VUS), unless there is evidence of tandem configuration.
Sinonasal Sarcomas Management: An International Consensus Statement
Caspani, F , Camarda, Anna Maria , Provenzano, Salvatore , Meço, Cem , Ferrari, Marco , Harrabi, Semi , Hosni, Ali, Italiano, Antoine, Vérillaud, Benjamin , Castelnuovo, Paolo, Nicolai, Piero, Su, Shirley Y. , Eloy, Jean Anderson , Fiore, Maria Rosaria, Palmer, James, Oliden, Victor Castro , Tos, Angelo Paolo Dei , Casali, Paolo G. , Dufresne, Armelle , Orlandi, Ester , Wormald, Peter‐John, Herman, Philippe , Carrau, Ricardo, Hanna, Ehab Y., Provenzano, Salvatore , Wang, Eric W , Ferrari, Marco , Schreiber, Alberto , Lechner, Matt , Eloy, Jean Anderson , Georgalas, Christos , Turri-Zanoni, Mario , Meço, Cem , Su, Shirley Y , Vinciguerra, Alessandro , Valentini, Marco , Šurda, Pavol , Campos, Fernando Augusto Batista , Martín‐Broto, Javier , Guadagnolo, B. Ashleigh , Navarria, Pierina , Hindi, Nadia , Italiano, Antoîne , Trifiletti, Daniel M. , Kasper, Bernd , Schreiber, Alberto , Castelnuovo, Paolo, Nicolai, Piero , Dallan, Iacopo , Chacón, Matías , Thariat, Juliette , Valverde, Claudia María , Lechner, Matt , Blay, Jean‐Yves , Brahmi, Mehdi , Greto, Daniela , Lugowska, Iwona A. , van Zele, Thibaut , Psaltis, Alkis J. , Sangalli, Claudia , Wormald, Peter‐John , Hanna, Ehab Y., Licitra, Lisa , Turri‐Zanoni, Mario , Battaglia, Paolo

Mayo Clinic

International Forum of Allergy & Rhinology | September 30, 2025 | Volume: 16 | Issue: 1 | Pages: 55-69

10.1002/alr.70038 | PMID 41025537 Get It

ABSTRACT Introduction Sinonasal sarcomas are exceedingly rare entities, constituting less than 7% of head and neck sarcomas. Their complex histology needs specialized treatment, which is often based on multimodal approaches including surgery, radiation therapy, and/or chemotherapy. This manuscript aims to gather expert opinions to establish common management principles for sinonasal sarcomas. Methods This international consensus followed a modified Delphi method in seven steps, including statements definition by the core group, expert panel recruitment, and a two‐round survey. Sixty‐two statements on sinonasal sarcoma management were developed. Experts from multiple continents participated, and results were anonymized and analyzed between March and May 2025. Results A total of 44 invited experts were recruited, 43.2% otorhinolaryngologists/head and neck surgeons, 31.8% medical oncologists, and 25% radiation oncologists. Participants varied in age and experience, representing Europe (70.5%), North America (18.2%), South America (6.8%), and Asia (4.5%). Among all histologies, biphenotypic sarcoma, chondrosarcoma, leiomyosarcoma, and myofibrosarcoma are principally treated with an upfront surgical management, differently from Ewing sarcoma and rhabdomyosarcoma in which chemotherapy, eventually associated with radiotherapy, is often chosen. In the remaining histologies (angiosarcoma, liposarcoma, malignant peripheral nerve sheath tumor [MPNST], osteosarcoma, and synovial sarcoma), a precise multimodal treatment is less standardized and needs to be discussed on a case‐by‐case basis. Conclusion Sinonasal sarcomas require a histology‐driven approach to determine upfront treatment, whether surgical, medical, or multimodal. Despite this structured strategy, prognosis remains highly variable across subtypes. Multidisciplinary evaluation and individualized management in referral centers are crucial to address the biological diversity and anatomical complexity of these rare malignancies.
Primary Care Clinician Preferences and Perspectives on Multi-Cancer Detection Testing Across an Integrated Healthcare System
Austin, Jessica D. , Nelson, Ilyse A., Tilburt, Jon C. , Ellinghysen, Eric R., Yee, Claire , Quillen, Jaxon , Dougan, Brian M. , Presutti, John R., Samadder, N. Jewel , Ghosh, Karthik, Ressler, Steven W. , Hurt, Ryan T. , Samadder, Niloy Jewel, Ressler, Steven W , Ghosh, Karthik , Austin, Jessica D , Yee, Claire , Quillen, Jaxon K , Nelson, Ilyse A.

Mayo Clinic

Journal of Personalized Medicine | September 29, 2025 | Volume: 15 | Issue: 10 | Pages: 452

10.3390/jpm15100452 | PMID 41149814 Get It

Background/Objectives: Multi-cancer detection (MCD) tests have emerged as a promising tool to redefine the landscape of early cancer detection. Implementation of this novel technology will likely fall to primary care clinicians (PCC). The purpose of this study is to characterize and explore differences in PCCs perceptions and preferences towards MCD testing. Methods: Between March and May of 2023, this cross-sectional survey was administered to 281 PCCs, including physicians and advanced care providers practicing within an integrated healthcare system spanning five states. The survey collected data on self-reported characteristics, perceptions of MCD testing, and preferences for learning about MCD testing. Analysis was limited to those with no prior experience with MCD testing (N = 181, response rate 22.8%). Descriptive statistics summarized key variables and chi-square tests assessed differences in perceptions and preferences by key characteristics. Results: Most PCCs were interested in MCD testing (66.3%), but limited knowledge/awareness of MCD testing and confidence to manage patients with a positive test were observed, along with concerns around cost (76.7%) and misuse/poor implementation. The primary preferences for learning about MCD testing were online courses or classroom instruction (64.5%). Significant differences in perceptions and preferences for learning were observed by location, degree, and years in practice. Conclusions: PCCs in our study held positive views towards MCD testing, but gaps and variation in knowledge and confidence towards MCD testing and concerns around the cost and misuse/poor implementation were observed. While efforts to train and educate all PCCs on MCD testing is a critical first step, more research is needed to understand how best to support implementation tailored to individual and system-level needs and characteristics.
Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment
Lee, Ikjae , Jang, Grace E. , Sherman, Alexander , Johnston, Wendy , Fernandes, Joseph Americo, Habib, Ali A. , Maragakis, Nicholas J. , Shah, Jaimin , Zinman, Lorne , Floeter, Mary Kay, Ajroud‐Driss, Senda , Gwathmey, Kelly , Heiman‐Patterson, Terry , Jawdat, Omar, Kasarskis, Edward J. , Kisanuki, Yaz Y. , Wymer, James , Fournier, Christina , Hayat, Ghazala , Heitzman, Daragh, Lomen‐Hoerth, Catherine , Pulley, Michael , Scelsa, Stephen N. , Walk, David , Shoesmith, Christen , Sorenson, Eric J. , Elman, Lauren , Harms, Matthew , Hoover, Benjamin N., Yun, RN ByoungSook, Santella, Regina M. , Mitsumoto, Hiroshi , Group, for the PLS NHS Study, Diaz, Frank , Maragakis, Nicholas , Oskarsson, Björn , Goutman, Stephen A , Sorenson, Eric, Walk, David , Cheung, Ken , Diaz, Frank , Fernandes, J. Americo, Paganoni, Sabrina , Burke, Katherine M. , Oskarsson, Björn , Goutman, Stephen A. , Simmons, Zachary , Harms, Matthew B. , Hoover, Benjamin N., Group, for the PLS NHS Study

Mayo Clinic

Annals of Neurology | September 29, 2025 | Volume: 99 | Issue: 2 | Pages: 418-428

10.1002/ana.78056 | PMID 41020440 Get It

Objective The primary lateral sclerosis ( PLS ) consensus diagnostic criteria and functional rating scale ( PLSFRS ) were recently established to facilitate and optimize future PLS clinical trials. We examined the trajectory of the PLSFRS and other functional outcome measures and biomarkers in the PLS Natural History Study ( PLS NHS ) to understand their performance in this prospective cohort. Methods The PLS NHS is a prospective, longitudinal, multicenter study of people living with PLS in different diagnostic categories: early (disease duration <2 years); probable (2–4 years); and definite PLS (4–15 years). PLSFRS scores and other functional outcome measures were collected at baseline, 3‐, 6‐, 9‐, and 12‐month follow‐up visits. Baseline characteristics were compared between the groups. The slopes of the PLSFRS and other functional outcome measures over 12 months were examined in the overall cohort and subgroups using linear mixed‐effect models. The associations between baseline characteristics and the rate of PLSFRS decline were analyzed with linear regression models. Results A total of 76 participants were included: early (n = 6); probable (n = 26); and definite (n = 44) PLS . Baseline PLSFRS total scores were highest in the early PLS group, followed by the probable and definite PLS groups. In the overall cohort, the PLSFRS total score declined by 0.33 points/month (95% confidence interval [0.27–0.39], adjusted p < 0.05). The rate of decline was steepest in the early PLS group, followed by the probable and definite PLS groups. Baseline neurofilament light chain level was associated with the rate of PLSFRS decline over 1 year ( p = 0.001). Interpretation In PLS, the rate of functional decline, as measured by the PLSFRS total score, is faster during the early phase of the disease. Neurofilament light might serve as a prognostic biomarker in PLS. ANN NEUROL 2026;99:418–428
Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity‐Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study
Brorson, James R. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M. , Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Melkumova, Emiliya , Dumitrascu, Oana M. , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Brown, Samantha , Kang, Jieun, Bowman, Anna, Shahrivari, Mahan, Sehgal, S , Alvi, Muhammad , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Qdais, Ahmad Abu, Quintela, Gustavo Antezana, Sharma, Richa, Thottempudi, Neeharika, Nedelcu, Simona , Herpich, Franziska , Glover, Patrick , Chahien, Dalia, Liebeskind, David S. , Linares, Guillermo , Daniel, Jean‐Philippe, Kasab, Sami Al , Singh, Eesha , D’Souza, Maria , Gaudio, Elizabeth, Kala, Narendra , Sarkar, Monica , Coevering, Russell J. Van , Thon, Jesse , Thompson, Sean, Lineback, Christina , Brorson, James R , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M , Khasiyev, Farid , Kerrigan, Deborah , Ali, Hamid , Aboul-Nour, Hassan , de Havenon, Adam H , Culbertson, Collin J , Melkumova, Emiliya , Jillella, Dinesh V , Dumitrascu, Oana M , Parikh, Parth , Sathya, Anvitha , Brown, Samantha J , Elangovan, Cheran , Sehgal, Siddharth , Sloane, Kelly L , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Farooqui, Mudassir , Nahab, Fadi B , Sharma, Richa , Nedelcu, Simona , Herpich, Franziska , Liebeskind, David S. , Linares, Guillermo , Al Kasab, Sami , Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric D , Van Coevering, Russell J , Thon, Jesse , Stamm, Brian , Siegler, James E , Lineback, Christina M , Daniel, Jean-Philippe Auguste , Smith, Matthew M. , Nour, Hassan Aboul , Havenon, Adam de , Jillella, Dinesh , Doolittle, Charles, Elangovan, Cheran , Sharma, Richa , Thottempudi, Neeharika , D'Souza, Marissa, Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric , Chen, Lucia , Stamm, Brian , Siegler, James E.

Mayo Clinic

Journal of the American Heart Association | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.041500 | PMID 40996035 Get It

Background Intracranial occlusions in embolic stroke of undetermined source are histopathologically similar to cardiac sources of embolism. Whether patients with embolic stroke of undetermined source and intracranial occlusion benefit from anticoagulation is unknown. Methods A multicenter retrospective cohort of adults with cryptogenic stroke was queried for patients with proximal or medium/distal vessel occlusion. The primary outcome was recurrent ischemic stroke, which was assessed in unadjusted and adjusted Cox proportional hazards models and repeated following 1:1 propensity score matching and biweight kernel density matching. Results Of the 2328 patients who were followed over a median of 1.31 years (interquartile range, 0.34–2.85), 999 (42.6%) had an intracranial occlusion. When compared with patients without an intracranial occlusion, those with an occlusion had fewer atherosclerotic vascular risk factors, more severe symptoms, and less severe cerebral microvascular disease. The rate of recurrent stroke was similar between patients with versus without an intracranial occlusion (6.8%/year [95% CI, 5.7–8.2] versus 7.0%/year [95% CI 6.0–8.1]; adjusted hazard ratio [HR], 1.09 [95% CI, 0.77–1.55]). There was no association between occlusion and recurrent stroke in the adjusted propensity score matching (HR, 1.01 [95% CI, 0.64–1.59]) or kernel density models (HR, 0.95 [95% CI, 0.62–1.45]). There was no interaction between occlusion and treatment with anticoagulation, sex, age, or high‐risk sources of embolism for the primary outcome in the unmatched and matched analyses. Conclusions Intracranial occlusion in patients with embolic stroke of undetermined source is not associated with a greater risk of recurrence when compared with patients without an intracranial occlusion. There was no difference in rate of recurrent stroke with anticoagulation when stratified by presence or absence of occlusion.
Male genitalia trauma. Recommendations from 5th International Consultation on Sexual Medicine (ICSM 2024)
Chung, Eric , Morey, Allen F. , Ziegelmann, Matt, Jenkins, Lawrence C. , Lin, Hsiao‐Han , Deveci, Serkan , Levine, Laurence A. , Seyam, Raouf , Broderick, Gregory, Jenkins, Lawrence , Deveci, Serkan , Morey, Allen F. , Moon, Du Geon , Broderick, Gregory A. , Lin, Hao Cheng

Mayo Clinic

Sexual Medicine Reviews | September 24, 2025 | Volume: 14 | Issue: 1 | Pages: No page available

10.1093/sxmrev/qeaf058 | PMID 41100212 Get It

Abstract Introduction The lower urinary tract injury, although often not life-threatening, can result in devastating long-term morbidity and, in some cases, permanent disability. Male genital trauma adversely affects male sexual function. Aim This 5th International Consultation on Sexual Medicine guideline on male genitalia trauma evaluates urologic trauma literature to guide clinicians in the best-evidenced management with specific emphasis on preservation and optimization of male sexual function. Methods A systematic literature search was conducted to identify relevant English-language publications and contemporary guidelines using the PubMed database (search dates January 1, 1990 to June 1, 2024) on the following terms: “trauma,” “penis,” “urethra,” “testis,” and “scrotum.” The available literature was discussed, and selected articles with the highest evidence available were used to create consensus guideline statements, categorized based on the Grading of Recommendations Assessment, Development and Evaluation system. In the absence of sufficient evidence, additional information was provided as a Clinical Principle or Expert Opinion. Results Fourteen recommendations are provided with corresponding levels of evidence and grades of recommendation. Conclusions Treating clinicians should be mindful that both the male genitalia trauma itself and treatment outcomes invariably affect various male sexual functions. Optimal treatment of male genitalia trauma is essential and should incorporate patient tolerances, needs, and preferences to minimize long-term sexual dysfunction.
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
McDade, Eric , Barthélemy, Nicolas R. , Wang, Guoqiao , Li, Yan , Cao, Yuchen , Clifford, David B., Goate, Alison , Renton, Alan E., Hassenstab, Jason , Perrin, Richard J. , Xiong, Chengjie , Mummery, Catherine J. , Berman, Sarah , Roberson, Erik D. , Dyck, Christopher van , Gauthier, Serge , Masters, Colin L. , Bittner, Tobias , Yaari, R. , Chhatwal, Jasmeer P. , Chrem, Patricio, Xiong, Chengjie , Ringman, John M. , Ryan, Natalie S. , Day, Gregory S. , Daniels, Alisha , Morris, John C., Supnet, Charlene , Team, The DIAN‐TU Study Team and DIAN Obs, McDade, Eric M , Bateman, Randall J , Roberson, Erik , Day, Gregory S , Masters, Colin L , Xiong, Chengjie , Hassenstab, Jason , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Gordon, Brian A. , Benzinger, Tammie L.S. , Renton, Alan , Llibre‐Guerra, Jorge J. , Xiong, Chengjie , Cruchaga, Carlos , Lah, James J. , Masellis, Mario , Brooks, William S. , Suzuki, Kazushi , Jucker, Mathias , Wallon, David , Ikeuchi, Takeshi , Lee, Jae‐Hong , Roh, Jee Hoon , Schofield, Peter R. , Fox, Nick C. , Vöglein, Jonathan , Karch, Celeste M. , Ibanez, Laura , Sánchez‐Valle, Raquel , Morris, John C. , Levey, Allan I. , Bateman, Randall J. , Team, The DIAN‐TU Study Team and DIAN Obs

Mayo Clinic

Alzheimer's & Dementia | September 23, 2025 | Volume: 21 | Issue: 9 | Pages: No page available

10.1002/alz.70689 | PMID 40985290 Get It

Abstract BACKGROUND Tau‐derived cerebrospinal fluid (CSF) biomarkers correlate with amyloid‐beta (Aβ) plaques or tau tangles in Alzheimer's disease (AD). This study assessed the effects of long‐term anti‐Aβ antibodies on amyloid plaques, tau tangles, and CSF tau species to determine the relationships between them. METHODS A post‐hoc analysis of the DIAN‐TU‐001 trial (NCT01760005) examined 142 participants at risk for dominantly inherited AD randomized to solanezumab ( n = 50), gantenerumab ( n = 52), or placebo ( n = 40). High‐resolution mass spectrometry quantified CSF tau species over four years. RESULTS Phosphorylated tau (p‐tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab‐mediated Aβ plaque reduction. Nearly a decade later, MTBR‐tau243 and p‐tau205 increased, showing no association with Aβ reduction, aligning with tau tangle pathology progression. DISCUSSION Initially changing soluble p‐tau species track Aβ plaque reduction, while ptau205 and MTBR‐243 reflect tau tangle pathology, informing different pathways of therapeutic strategies. Highlights p‐tau217 and p‐tau231 correlate with Aβ‐PET and respond to Aβ‐plaque lowering therapies. Aβ immunotherapy trials support a direct link between p‐tau changes and Aβ plaques Gantenerumab reduces Aβ plaques but does not affect tau NFT‐related biomarkers. Blood‐based p‐tau217 assays may provide a non‐invasive tool to monitor Aβ therapies. MTBR‐tau243 strongly correlates with tau PET and tracks NFT pathology progression. Further studies are needed to validate tau biomarkers for tracking NFT‐targeting therapies.